Observational study / 2019
Higher serum TMAO levels were linked to first-ever acute ischemic stroke and greater stroke severity in Chinese patients.
A case-control study evaluated serum TMAO levels in 255 consecutive patients with first-ever acute ischemic stroke and 255 age- and gender-matched healthy controls. Median TMAO levels were higher in stroke patients (5.8 μM; IQR, 3.3-10.0) than in controls (3.9 μM; IQR, 2.6-6.1). Patients with moderate-to-high stroke severity (NIHSS > 6) had higher median TMAO than minor stroke patients (9.1 μM vs. 4.1 μM, P<0.001). Each 1 μM increase in TMAO was associated with a 22% increased multivariable-adjusted risk of moderate-to-high stroke (OR = 1.22; 95% CI: 1.08-1.32; P<0.001).
Shows an association, not proof of cause and effect.
- Study type
- Case-control study
- Who was studied
- 255 patients with first-ever acute ischemic stroke and 255 matched healthy controls in China
- What was measured
- Serum TMAO levels and stroke severity based on the NIH Stroke Scale (NIHSS)
THE PAPER
Serum levels of Trimethylamine-N-oxide in patients with ischemic stroke.
Rexidamu M, Li H, Jin H, Huang J. Biosci Rep, 2019.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.